Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT01248767
Recruiting Observational

A Prospective Clinical Study of a Cohort of Patients Seeking Treatment for a Behavioral Addiction

NCT01248767 · tracked via the Priya Life Science France tracker
Sponsor
Nantes University Hospital
Phase
Observational
Started
2019-03-28
Last updated
2025-11-24

Condition(s) studied

Behavioral Addictions

Study summary

This research aims to provide a better understanding of the factors associated with the evolution of behavioral addictions, and compliance with care. The investigators thus aim to follow patients with several types of behavioral addictions, based on addictive, sociodemographic, clinical and endophenotypical characteristics, as well as their care adhesion.

Eligibility

Sex
ALL
Min age
15 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : \- All consecutive patients seeking treatment at the University Hospital of Nantes for a behavioral addiction and age over 15 will be allowed to participate to the study. Exclusion Criteria : * Cognitive impairment incompatible with the assessment * Difficulty for writing or reading the French language, incompatible with the assessement * Gardianship

Primary outcome measure(s)

  • Evolution of behavioral addictions — 8 years
    Understand what determines the evolution of behavioral addictions and compliance with care. Study the outcome of patients with behavioral addictions, both in terms of the evolution of of the addictive pathology and associated clinical and endophenotypic characteristics, as well as adherence to care.

Trial sites (1)

FacilityCityRegionStatus
Nantes University Hospital Nantes France Recruiting

More Nantes University Hospital trials in France

Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses Recruiting
Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects Recruiting
French Clinical Datbase of Melanoma Patients (RIC-Mel) Recruiting
Research Project on the Risk of Discomfort, Pain, Alteration of Skin Condition in Bedpan Use by Patients and Caregivers Recruiting
Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01248767 on ClinicalTrials.gov ↗ ← All trials in France